Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

Abstract

BACKGROUND:

In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. We report on the incidence, time course, severity, and resolution of treatment-emergent adverse events (AEs) as well as incidence of dose modifications during the extended follow-up of this study.

PATIENTS AND METHODS:

Patients were randomized (2:1) to receive EVE 10 mg/day or placebo (PBO), with open-label EXE 25 mg/day (n = 724). The primary end point was progression-free survival. Secondary end points included overall survival, objective response rate, and safety. Safety evaluations included recording of AEs, laboratory values, dose interruptions/adjustments, and study drug discontinuations.

RESULTS:

The safety population comprised 720 patients (EVE + EXE, 482; PBO + EXE, 238). The median follow-up was 18 months. Class-effect toxicities, including stomatitis, pneumonitis, and hyperglycemia, were generally of mild or moderate severity and occurred relatively early after treatment initiation (except pneumonitis); incidence tapered off thereafter. EVE dose reduction and interruption (360 and 705 events, respectively) required for AE management were independent of patient age. The median duration of dose interruption was 7 days. Discontinuation of both study drugs because of AEs was higher with EVE + EXE (9%) versus PBO + EXE (3%).

CONCLUSIONS:

Most EVE-associated AEs occur soon after initiation of therapy, are typically of mild or moderate severity, and are generally manageable with dose reduction and interruption. Discontinuation due to toxicity was uncommon. Understanding the time course of class-effect AEs will help inform preventive and monitoring strategies as well as patient education.

TRIAL REGISTRATION NUMBER:

NCT00863655.

• Authors: H S Rugo, K I Pritchard, M Gnant, S Noguchi, M Piccart, G Hortobagyi, J Baselga, A Perez, M Geberth, T Csoszi, E Chouinard, V Srimuninnimit, P Puttawibul, J Eakle, W Feng, H Bauly, M El-Hashimy, T Taran, H A Burris 3rd
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 25 Issue 4 Pg. 808-815 (Apr 2014) ISSN: 1569-8041 [Electronic] England
• PMID: 24615500 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Everolimus
• MTOR protein, human
• TOR Serine-Threonine Kinases
• Sirolimus

Topics

• Adult
• Aged
• Aged, 80 and over
• Breast Neoplasms (drug therapy, genetics, pathology)
• Disease-Free Survival
• Drug-Related Side Effects and Adverse Reactions (classification, pathology)
• Everolimus
• Female
• Humans
• Middle Aged
• Neoplasm Staging
• Postmenopause
• Sirolimus (administration & dosage, adverse effects, analogs & derivatives)
• TOR Serine-Threonine Kinases (genetics)